Singapore Clinical Trial: A Phase 3 Open-label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment with a CDK4/6 Inhibitor

Singapore, May 14 -- The Health Sciences Authority received information related to the study titled 'A Phase 3 Open-label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant V... Read More

Singapore Clinical Trial: A randomized, double-blind, placebo-controlled study to evaluate the effect of dupilumab on airway inflammation through assessments of mucus plugging and other lung imaging parameters in patients with chronic obstructive pulmonary disease

Singapore, May 14 -- The Health Sciences Authority received information related to the study titled 'A randomized, double-blind, placebo-controlled study to evaluate the effect of dupilumab on airway ... Read More

Singapore Clinical Trial: CA088-1007: A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Singapore, May 14 -- The Health Sciences Authority received information related to the study titled 'CA088-1007: A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety... Read More

Singapore Clinical Trial: A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lutetium-177 (177Lu) Rosopatamab Tetraxetan in Combination with Standard of Care Versus Standard of Care Alone in Patients with Prostate-Specific Membrane Antigen (PSMA) Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) after Androgen Receptor Pathway Inhibitor (ARPI) Treatment

Singapore, May 14 -- The Health Sciences Authority received information related to the study titled 'A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lut... Read More

Singapore Clinical Trial: CO45042: A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib Plus Pembrolizumab Versus Pembrolizumab And Pemetrexed And Carboplatin or Cisplatin in Patients with Previously Untreated, KRAS G12C-Mutated, Advanced Or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Singapore, May 14 -- The Health Sciences Authority received information related to the study titled 'CO45042: A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib ... Read More

Singapore Clinical Trial: A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigator’s Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

Singapore, May 14 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durv... Read More

Singapore Clinical Trial: TulmiSTAR-01: A two-part, Phase I dose escalation and expansion followed by a randomized, open-label multicenter, Phase II study to assess the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) vs standard of care in patients with progressive metastatic castrate resistant prostate cancer

Singapore, May 14 -- The Health Sciences Authority received information related to the study titled 'TulmiSTAR-01: A two-part, Phase I dose escalation and expansion followed by a randomized, open-labe... Read More

Singapore Clinical Trial: A Master Protocol of an Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumour Activity of Novel Combinations in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (LIBRA)

Singapore, May 14 -- The Health Sciences Authority received information related to the study titled 'A Master Protocol of an Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety... Read More

Trump Says U.S.-China Relations Will Be 'Better Than Ever' After Xi Meeting

Afghanistan, May 14 -- Donald Trump expressed optimism about future ties between the United States and China during high-level talks with Xi Jinping in Beijing on Thursday. According to Fox News, Tru... Read More

Nigeria's petrol imports fall as local refineries raise output - NMDPRA

Nigeria, May 14 -- Nigeria's dependence on imported petrol declined further in April as domestic refineries increased output and operated at near full capacity, the Nigerian Midstream and Downstream P... Read More

• ««
• «
• 18989
• 18990
• 18991
• 18992
• 18993
• 18994
• 18995
• 18996
• 18997
• 18998
• »
• »»